The Latest
-
Deep Dive
Biotech M&A is on the upswing. Track the latest deals here.
Drugmakers have inked at least 16 buyouts worth $50 million or more so far this year, up from the 11 recorded over the same period in 2023.
Updated 7 hours ago -
Sponsored by Fortrea
Systems thinking: A new paradigm for clinical trial design and operations
Applying a systems thinking framework to clinical trial design prompts purposeful and productive collaboration among stakeholders.
-
FDA finalizes lab developed test rule over industry opposition
Risks associated with the tests have increased, requiring greater oversight to protect patients, the agency contends.
-
Prime gets FDA green light to begin first trial test of ‘prime editing’
The company will soon start a Phase 1/2 study of its treatment for chronic granulomatous disease, a milestone for the search-and-replace gene editing technology.
-
Emerging biotech
Repertoire pivot pays dividends with Bristol Myers deal
The alliance validates the new direction pursued by Repertoire, a startup that cut staff and switched CEOs in 2022 after research on personalized cell therapies disappointed.
-
Pfizer hemophilia gene therapy arrives in US to uncertain future
The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition struggle to gain traction.
-
Deep Dive
Biotech IPOs are the industry’s lifeblood. Track how they’re performing.
Cancer drug startup Lirum Pharmaceuticals set terms for what could be the 11th IPO so far this year. But it would also be one of the smallest, with about $25 million in anticipated proceeds.
Updated April 19, 2024 -
BioMarin drops drug programs in pipeline cull
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.
-
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.
-
Gene editing
Regeneron expands in gene editing with Mammoth deal
“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.
-
Biogen: Don’t expect any big acquisitions this year
While the company is eager to diversify, CEO Chris Viehbacher said any near-term dealmaking would likely focus on collaborations and early-stage assets.
-
Moderna turns to AI to change how its employees work
An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes.
-
Biogen sees ‘encouraging’ trends for postpartum depression drug
First quarter sales of Zurzuvae doubled consensus estimates, though analysts are skeptical whether the better-than-expected launch will continue.
-
CureVac to cut costs in restructuring
The mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will eliminate 150 positions.
-
Emerging biotech
Endeavor pulls in $132M to back cancer, lung disease drugs
Led by the founder of a biotech Celgene acquired for $7 billion, the startup is developing two prospects that originated in the labs of other drugmakers.
Updated April 24, 2024 -
New Alzheimer's drugs
Biogen to invest more in launch of Alzheimer’s drug Leqembi
Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30%.
-
Novartis raises forecasts as top drug sales beat Wall Street estimates
Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.
-
Former Bristol Myers CEO tapped as Novartis’ next board chair
Giovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed Novartis’ longtime board chair Joerg Reinhardt next year.
-
Neurocrine scores surprise win with depression drug
Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.
-
FDA rejects Abeona cell therapy, asks for more manufacturing data
The complete response letter for Abeona’s treatment is one of several manufacturing setbacks for cell and gene therapy developers in recent years.
-
Lilly to buy injectable drug plant in manufacturing ramp-up
The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.
-
Bristol Myers taps startup to boost cell therapy production
A partnership with Cellares, worth up to $380 million, is meant to help Bristol Myers speed and scale manufacture of CAR-T treatments for cancer.
-
Pharmas form joint venture to jumpstart Japanese drug research
A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.
-
Eisai hunts for next Alzheimer’s drug with new research pact
A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.
-
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA.
-
Alvotech deal could heighten biosimilar pressure on Humira
The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.